ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -8 مورد

Dicloxacillin: Drug information

Dicloxacillin: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Dicloxacillin: Patient drug information" and "Dicloxacillin: Pediatric drug information"

For abbreviations, symbols, and age group definitions show table
Pharmacologic Category
  • Antibiotic, Penicillin
Dosing: Adult
Endocarditis, treatment, oral step-down therapy

Endocarditis, treatment, oral step-down therapy: Note: Not first-line therapy; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for methicillin-susceptible S. aureus infection but cannot complete IV standard of care therapy (Ref).

Oral: 1 g 4 times daily in combination with rifampin for a total duration, including initial IV therapy, of 6 weeks (Ref).

Mastitis, lactational

Mastitis, lactational: Note: Reserve for nonsevere infection in the absence of risk for resistant pathogens (eg, methicillin-resistant S. aureus).

Oral: 500 mg 4 times daily for 10 to 14 days; shorter courses (eg, 5 to 7 days) may be considered for patients with rapid clinical resolution (Ref).

Prosthetic joint infection

Prosthetic joint infection (alternative agent): Oral continuation therapy for methicillin-susceptible S. aureus (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis):

Oral: 500 mg 3 or 4 times daily (Ref). Note: Duration ranges from a minimum of 3 months to indefinitely, depending on patient-specific factors. For the first 3 to 6 months of therapy, combine with rifampin (Ref).

Skin and soft tissue infection

Skin and soft tissue infection:

Note: Not an appropriate agent if methicillin-resistant S. aureus is suspected or confirmed (Ref).

Cellulitis (nonpurulent)/erysipelas, mild: Oral: 500 mg 4 times daily for 5 days; duration may be extended up to 14 days if not resolved/slow response (Ref).

Impetigo or ecthyma: Note: For impetigo, reserve systemic therapy for patients with numerous lesions or in outbreak settings to decrease transmission (Ref).

Oral: 250 to 500 mg 4 times daily for 7 days (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no specific dosage adjustments provided in the manufacturer’s labeling; a reduction in total dosage should be considered in renal impairment.

Hemodialysis: Not dialyzable; supplemental dose is not necessary (Ref).

Peritoneal dialysis effects: Supplemental dose is not necessary (Ref).

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Dicloxacillin: Pediatric drug information")

General dosing: Infants, Children, and Adolescents: Oral: 3 to 6.25 mg/kg/dose every 6 hours; maximum dose: 250 mg/dose. Higher doses are recommended for some infections (eg, osteoarticular infections, skin and soft tissue infections) (Ref).

Osteoarticular infection; eg, septic arthritis, osteomyelitis

Osteoarticular infection; eg, septic (bacterial) arthritis, osteomyelitis: Step-down therapy following parenteral treatment:

Infants, Children, and Adolescents: Oral: 25 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose (Ref). Minimum total duration is 2 to 3 weeks for septic arthritis and 3 to 4 weeks for osteomyelitis; however, duration is often longer and individualized based on several factors, including causative pathogen, response to therapy, and normalization of inflammatory markers (Ref).

Skin and soft tissue infection, methicillin-susceptible Staphylococcus aureus

Skin and soft tissue infection, methicillin-susceptible Staphylococcus aureus (MSSA): Infants, Children, and Adolescents: Oral: 6.25 to 12.5 mg/kg/dose every 6 hours; maximum dose: 500 mg/dose (Ref).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: There are no specific dosage adjustments provided in the manufacturer’s labeling; a reduction in total dosage should be considered.

Hemodialysis: Not dialyzable.

Peritoneal dialysis: Not dialyzable.

Dosing: Liver Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer’s labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for dicloxacillin.

Postmarketing:

Dermatologic: Skin photosensitivity (acute exanthematous pustulosis; Nielsen 2020), skin rash (Drivenes 2022)

Endocrine & metabolic: Hypokalemia (Johnson 2002)

Gastrointestinal: Cholestasis (Gosbell 2000), Clostridioides difficile colitis, diarrhea, esophageal ulcer, esophagitis, hairy tongue, heartburn, melanoglossia, nausea, stomatitis, vomiting

Hematologic & oncologic: Agranulocytosis, anemia, eosinophilia, granulocytopenia, hemolytic anemia, leukopenia, neutropenia, thrombocytopenia

Hepatic: Cholestatic hepatitis (Kleinman 1986), hepatotoxicity (Gosbell 2000), increased serum alanine aminotransferase, increased serum alkaline phosphatase, increased serum aspartate aminotransferase

Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, serum sickness-like reaction, type 1 hypersensitivity reaction and type IV hypersensitivity reaction)

Renal: Interstitial nephritis (Gosbell 2000), renal insufficiency (Gosbell 2000), renal tubular disease

Contraindications

Hypersensitivity to dicloxacillin, other penicillins, or any component of the formulation.

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity reactions: Serious and occasionally fatal hypersensitivity (anaphylactic shock with collapse) reactions have been reported in patients on penicillin therapy. Initiate therapy only after a comprehensive drug and allergy history; use with caution in patients with a history of significant allergies and/or asthma. Discontinue use and institute appropriate therapy if a hypersensitivity reaction occurs.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Capsule, Oral:

Generic: 250 mg, 500 mg

Generic Equivalent Available: US

Yes

Pricing: US

Capsules (Dicloxacillin Sodium Oral)

250 mg (per each): $1.38 - $1.50

500 mg (per each): $2.51 - $2.73

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Oral: Administer 1 hour before or 2 hours after meals with at least 120 mL of water. Should not be administered in the supine position or immediately before going to bed.

Administration: Pediatric

Oral: Administer with water 1 hour before or 2 hours after meals with at least 120 mL (4 ounces) of water; should not be administered in the supine position or immediately before going to bed.

Use: Labeled Indications

Staphylococcal infections: Treatment of infections caused by penicillinase-producing staphylococci.

Medication Safety Issues
Pediatric patients: High-risk medication:

KIDs List: Dicloxacillin, when used in neonates, is identified on the Key Potentially Inappropriate Drugs in Pediatrics (KIDs) list and should be used with caution due to risk of kernicterus (weak recommendation; very low quality of evidence) (PPA [Meyers 2020]).

Metabolism/Transport Effects

Substrate of OAT1/3; Induces CYP2C19 (Moderate), CYP3A4 (Weak);

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Abrocitinib: CYP2C19 Inducers (Moderate) may decrease serum concentration of Abrocitinib. Risk C: Monitor

Acemetacin: May increase serum concentration of Penicillins. Risk C: Monitor

Aminoglycosides: Penicillins may decrease serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction. Risk C: Monitor

Atogepant: CYP3A4 Inducers (Weak) may decrease serum concentration of Atogepant. Management: For treatment of episodic migraine, the recommended dose of atogepant is 30 mg once daily or 60 mg once daily when combined with CYP3A4 inducers. When used for treatment of chronic migraine, use of atogepant with CYP3A4 inducers should be avoided. Risk D: Consider Therapy Modification

Bacillus clausii: Antibiotics may decrease therapeutic effects of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider Therapy Modification

BCG (Intravesical): Antibiotics may decrease therapeutic effects of BCG (Intravesical). Risk X: Avoid

BCG Vaccine (Immunization): Antibiotics may decrease therapeutic effects of BCG Vaccine (Immunization). Risk C: Monitor

Brivaracetam: CYP2C19 Inducers (Moderate) may decrease serum concentration of Brivaracetam. Risk C: Monitor

CarBAMazepine: CYP3A4 Inducers (Weak) may decrease serum concentration of CarBAMazepine. Risk C: Monitor

Carisoprodol: CYP2C19 Inducers (Moderate) may decrease serum concentration of Carisoprodol. CYP2C19 Inducers (Moderate) may increase active metabolite exposure of Carisoprodol. Risk C: Monitor

Cholera Vaccine: Antibiotics may decrease therapeutic effects of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid

CloZAPine: CYP3A4 Inducers (Weak) may decrease serum concentration of CloZAPine. Risk C: Monitor

DiazePAM: CYP2C19 Inducers (Moderate) may decrease serum concentration of DiazePAM. Risk C: Monitor

Dichlorphenamide: Penicillins may increase hypokalemic effects of Dichlorphenamide. Risk C: Monitor

Etravirine: CYP2C19 Inducers (Moderate) may decrease serum concentration of Etravirine. Risk C: Monitor

Fecal Microbiota (Live) (Oral): May decrease therapeutic effects of Antibiotics. Risk X: Avoid

Fecal Microbiota (Live) (Rectal): Antibiotics may decrease therapeutic effects of Fecal Microbiota (Live) (Rectal). Risk X: Avoid

Fosphenytoin-Phenytoin: CYP2C19 Inducers (Moderate) may decrease serum concentration of Fosphenytoin-Phenytoin. Risk C: Monitor

Hormonal Contraceptives: CYP3A4 Inducers (Weak) may decrease serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability. Risk D: Consider Therapy Modification

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may decrease therapeutic effects of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor

Lactobacillus and Estriol: Antibiotics may decrease therapeutic effects of Lactobacillus and Estriol. Risk C: Monitor

Mavacamten: CYP2C19 Inducers (Moderate) may decrease serum concentration of Mavacamten. Risk X: Avoid

Methadone: CYP2C19 Inducers (Moderate) may decrease serum concentration of Methadone. Risk C: Monitor

Methotrexate: Penicillins may increase serum concentration of Methotrexate. Risk C: Monitor

Mycophenolate: Antibiotics may decrease active metabolite exposure of Mycophenolate. Specifically, concentrations of mycophenolic acid (MPA) may be reduced. Risk C: Monitor

Nelfinavir: CYP2C19 Inducers (Moderate) may decrease serum concentration of Nelfinavir. Risk C: Monitor

NiMODipine: CYP3A4 Inducers (Weak) may decrease serum concentration of NiMODipine. Risk C: Monitor

Omeprazole: CYP2C19 Inducers (Moderate) may decrease serum concentration of Omeprazole. Risk C: Monitor

Ospemifene: Dicloxacillin may decrease serum concentration of Ospemifene. Risk C: Monitor

PHENobarbital: CYP2C19 Inducers (Moderate) may decrease serum concentration of PHENobarbital. Risk C: Monitor

Probenecid: May increase serum concentration of Penicillins. Risk C: Monitor

Selpercatinib: CYP3A4 Inducers (Weak) may decrease serum concentration of Selpercatinib. Risk C: Monitor

Sirolimus (Conventional): CYP3A4 Inducers (Weak) may decrease serum concentration of Sirolimus (Conventional). Risk C: Monitor

Sirolimus (Protein Bound): CYP3A4 Inducers (Weak) may decrease serum concentration of Sirolimus (Protein Bound). Risk C: Monitor

Sodium Benzoate: Penicillins may decrease therapeutic effects of Sodium Benzoate. Risk C: Monitor

Sodium Picosulfate: Antibiotics may decrease therapeutic effects of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider Therapy Modification

Tacrolimus (Systemic): CYP3A4 Inducers (Weak) may decrease serum concentration of Tacrolimus (Systemic). Risk C: Monitor

Tetracyclines: May decrease therapeutic effects of Penicillins. Risk C: Monitor

Typhoid Vaccine: Antibiotics may decrease therapeutic effects of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider Therapy Modification

Ubrogepant: CYP3A4 Inducers (Weak) may decrease serum concentration of Ubrogepant. Management: Use an initial ubrogepant dose of 100 mg and second dose (if needed) of 100 mg when used with a weak CYP3A4 inducer. Risk D: Consider Therapy Modification

Vitamin K Antagonists: Dicloxacillin may decrease anticoagulant effects of Vitamin K Antagonists. Risk C: Monitor

Voriconazole: CYP2C19 Inducers (Moderate) may decrease serum concentration of Voriconazole. Risk C: Monitor

Food Interactions

Food decreases drug absorption rate and serum concentration. Management: Administer on an empty stomach with a large glass of water 1 hour before or 2 hours after meals.

Pregnancy Considerations

Dicloxacillin crosses the placenta (Depp 1970; MacAulay 1968; Seiga 1974).

Penicillin class antibiotics cross the placenta in varying degrees. Dicloxacillin is highly protein bound, which may influence fetal exposure (Nau 1987).

As a class, penicillin antibiotics are widely used in pregnant women. Based on available data, penicillin antibiotics are generally considered compatible for use during pregnancy (Ailes 2016; Bookstaver 2015; Crider 2009; Damkier 2019; Lamont 2014; Muanda 2017a; Muanda 2017b).

Breastfeeding Considerations

Dicloxacillin is present in breast milk (Matsuda 1984; Muysson 2020).

Data related to the presence of dicloxacillin in breast milk has been located from 2 studies.

• A single oral dose of dicloxacillin 250 mg was administered to 2 or 3 women 5 to 7 days postpartum. Breast milk concentrations were ≤0.3 mcg/mL over a 6-hour period, with the highest concentrations observed 4 hours after the maternal dose. In contrast, the highest maternal serum concentration (5.2 mcg/mL) was found 1 hour after the dose, decreasing to ≤0.4 mcg/mL 6 hours after the dose (Matsuda 1984). Using a breast milk concentration of 0.3 mcg/mL, the relative infant dose (RID) of dicloxacillin is 0.09% to 0.18% compared to an infant therapeutic dose of 25 to 50 mg/kg/day, providing an estimated daily infant dose via breast milk of 0.045 mg/kg/day.

• The RID of dicloxacillin was calculated by the authors of a second study following multiple doses for the treatment of mastitis. Included were 3 women, 1 to 6 months postpartum, receiving dicloxacillin 500 mg every 6 hours; breast milk was sampled at intervals from 0 to 6 hours after the maternal dose on or after the fourth day of therapy. The highest breast milk concentration was 0.0676 mcg/mL, which occurred 4 hours after the maternal dose. Authors of the study calculated the RID of dicloxacillin to be 0.03% of the weight-adjusted maternal dose, providing an estimated daily dose of 0.008 mg/kg/day via breast milk (Muysson 2020).

• In general, breastfeeding is considered acceptable when the RID is <10% (Anderson 2016; Ito 2000).

In general, antibiotics that are present in breast milk may cause non–dose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).

Although the manufacturer recommends that caution be exercised when administering dicloxacillin to patients who are breastfeeding, penicillins are considered compatible with breastfeeding when used in usual recommended doses (WHO 2002).

Dicloxacillin is a recommended antibiotic for the empiric treatment of bacterial mastitis in patients who are breastfeeding. Antibiotic use may be considered when symptoms are present for >24 hours and have not responded to conservative measures, or the patient has symptoms such as fever or tachycardia. Consider a milk culture if symptoms do not improve after 48 hours of antibiotic therapy. The diagnosis of mastitis does not require interruption of breastfeeding (ABM [Mitchell 2022]; WHO 2000).

Monitoring Parameters

Baseline and periodic CBC with differential; periodic BUN, serum creatinine, AST and ALT (especially with prolonged therapy); prothrombin time if patient concurrently on warfarin; signs of anaphylaxis during first dose

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: Rapid and incomplete; reduced by food.

Distribution: CSF penetration is low.

Vd:

Infants and Children: 0.295 ± 0.092 L/kg (range: 0.08 to 0.512 L/kg) (Smith 1990).

Adults: 5.99 L; increased in patients with ESRD on IHD (Nauta 1976).

Protein binding: 95% to 99% (primarily albumin).

Bioavailability:

Infants and Children: 59.89% ± 24.44% (Smith 1990).

Adults: 49% to 76% (Nauta 1976).

Half-life elimination:

Infants and Children: 32 minutes (Smith 1990).

Adults: ~0.7 hours; prolonged with renal impairment (Nauta 1976).

Time to peak, serum:

Infants and Children: 1.68 ± 0.84 hours (range: 0.58 to 3.7 hours) (Smith 1990).

Adults: 1 to 1.5 hours.

Excretion: Feces; urine (as unchanged drug):

Neonates: Prolonged.

Patients with CF: More rapid excretion than patients without CF (Jusko 1975).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy:

Time dependent, associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC); goal: ≥50% fT > MIC (Craig 1996; Craig 1998; Craig 2003; Drusano 2003).

Expected drug exposure in patients with normal renal function:

Cmax (peak): Oral:

Infants and children: 25 mg/kg/dose every 6 hours (after 2 to 6 doses): 14.347 ± 6.765 mg/L (range: 2 to 29.9 mg/L) (Smith 1990).

Adults: Single dose: 500 mg once: 10 to 17 mg/L (manufacturer's labeling); other data suggest variability (ie, range: 4.9 to 6.3 mg/L [Alderete 2004] vs mean 24.28 ± 10.72 mg/L [Wu 2015]).

Postantibiotic effect: Minimal bacterial killing continues after dicloxacillin concentration falls below the MIC of targeted pathogen and may vary based on the organism:

Staphylococcus aureus: 0 to 2.3 hours (Isaksson 1993; Li 1997).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Diclocil;
  • (AU) Australia: Diclocil | Dicloxacillin mylan | Dicloxacillin viatris | Dicloxsig | Distaph;
  • (BD) Bangladesh: Diclox;
  • (CO) Colombia: Bamaxin | Beciprof | Clobetcina | Cloxidin | Cloxil | Damacir | Diclocil | Diclogran | Diclomax | Diclosan | Diclotin | Diclovert | Diclox | Dicloxacilina | Dixalin | Dixapidin | Impo diclox | Masdiclox | Odontocil | Prediclex | Servidiclox | Xalin;
  • (DE) Germany: Infectostaph;
  • (DO) Dominican Republic: Diclocil | Dicloxacilina | Dicloxacilina Alfa | Ditterolina | Dixalin | Posipen | Xalin;
  • (EC) Ecuador: Cloxagen | Cloxin | Diclocil | Dicloxacilina | Dicloxacilina hg | Dicloxacilina MK | Dicloxacilina R | Dicloxen | Dicloxina | Dixalin | H.G. Dicloxacil;
  • (FI) Finland: Diclocil;
  • (FR) France: Diclocil;
  • (GR) Greece: Diclocil;
  • (HK) Hong Kong: Odicoza | Quali-Dicloxin | Ziefmycin;
  • (ID) Indonesia: Diclopen | Dicloxacillin | Dynapen;
  • (IN) India: Klox D;
  • (IS) Iceland: Staklox;
  • (JP) Japan: Diclex | Staphcillin a;
  • (LU) Luxembourg: Diclocil;
  • (MX) Mexico: Amifarin | Antiben | Brispen | Butimaxil | Clomicin | Coxaclan | Diamsalina | Dic fhi | Dicleophen | Diclotecno | Dicloxacil. gi | Dicloxacili.gi mer | Dicloxacilina | Dicloxacilina gi d | Dicloxacilina GI S | Dicloxacilina landsteiner | Dicloxacillin | Dicloxaquim | Dimicin | Ditterolina | Dixen | Doxil | Iclox | Ormopen | Penclox | Posipen | Xozacil;
  • (NO) Norway: Dicillin | Diclin | Diclocil | Dicloxacillin alternova | Dicloxacillin bluefish | Dicloxacillin orion;
  • (NZ) New Zealand: Diclocil;
  • (PE) Peru: Dermicilina | Diclobact | Diclobal | Diclocil | Diclomax | Dicloxacilina | Dicloxal | Dicloxil | Dicloxina | Dilovet | Dinapen | Dyclobiot | Plicben | Posipen | Vacloxipen;
  • (PR) Puerto Rico: Dicloxacillin | Dicloxacillin sodium | Dynapen;
  • (PT) Portugal: Diclocil;
  • (SE) Sweden: Diclocil | Dikloxacillin AstraZeneca | Dikloxacillin meda;
  • (TH) Thailand: Amcidil | Clox med | Cloxydin | D cloxa | Deoclox | Dicapzo | Dicillin | Diclex | Diclocil | Diclocillin | Diclohof | Diclomed | Diclonox | Dicloson | Diclox | Dicloxa | Dicloxacillin | Dicloxane | Dicloxapen | Dicloxgen | Dicloxhim | Dicloxia | Dicloximed | Dicloxin | Dicloxlin | Dicloxman | Dicloxno | Dicloxpac | Diloxin | Dimocin | Dixalin | Dixocillin | Dorox | Kressdixa | Madiclox | Phardicin | Servidiclox | Staphocil;
  • (TW) Taiwan: Dacocilin | Diclocil | Diclocin | Diclox | Dicloxacillin | Ziefmycin;
  • (VE) Venezuela, Bolivarian Republic of: Diclocil | Dicloxacilina
  1. Ailes EC, Gilboa SM, Gill SK, et al. Association between antibiotic use among pregnant women with urinary tract infections in the first trimester and birth defects, National Birth Defects Prevention Study 1997 to 2011. Birth Defects Res A Clin Mol Teratol. 2016;106(11):940-949. doi:10.1002/bdra.23570 [PubMed 27891788]
  2. Alderete O, González-Esquivel DF, Del Rivero LM, Castro Torres N. Liquid chromatographic assay for dicloxacillin in plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;805(2):353-356. doi:10.1016/j.jchromb.2004.03.006 [PubMed 15135112]
  3. American Academy of Pediatrics. Dicloxacillin. In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. Elk Grove Village, IL: American Academy of Pediatrics; 2021.
  4. American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). Pediatrics. 1997;99(2):268-278. [PubMed 9024461]
  5. Anderson PO, Sauberan JB. Modeling drug passage into human milk. Clin Pharmacol Ther. 2016;100(1):42-52. [PubMed 27060684]
  6. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children. 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  7. Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 22, 2021.
  8. Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed May 16, 2022a.
  9. Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. Circulation. 2022b;146(14):e187-e201. doi:10.1161/CIR.0000000000001090 [PubMed 36043414]
  10. Bookstaver PB, Bland CM, Griffin B, Stover KR, Eiland LS, McLaughlin M. A review of antibiotic use in pregnancy. Pharmacotherapy. 2015;35(11):1052-1062. doi:10.1002/phar.1649 [PubMed 26598097]
  11. Bradley JS, Nelson JD, eds. Nelson's Pediatric Antimicrobial Therapy. 28th ed. American Academy of Pediatrics; 2022.
  12. Bryson YJ, Connor JD, LeClerc M, Giammona ST. High-dose oral dicloxacillin treatment of acute staphylococcal osteomyelitis in children. J Pediatr. 1979;94(4):673-675. doi:10.1016/s0022-3476(79)80049-9 [PubMed 430319]
  13. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis. 1996;25(4):213-217. doi:10.1016/s0732-8893(96)00162-9 [PubMed 8937847]
  14. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am. 2003;17(3):479-501. doi:10.1016/s0891-5520(03)00065-5 [PubMed 14711073]
  15. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284 [PubMed 9455502]
  16. Crider KS, Cleves MA, Reefhuis J, Berry RJ, Hobbs CA, Hu DJ. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med. 2009;163(11):978-985. doi:10.1001/archpediatrics.2009.188 [PubMed 19884587]
  17. Damkier P, Brønniche LMS, Korch-Frandsen JFB, Broe A. In utero exposure to antibiotics and risk of congenital malformations: a population-based study. Am J Obstet Gynecol. 2019;221(6):648.e1-648.e15. doi:10.1016/j.ajog.2019.06.050 [PubMed 31260651]
  18. Depp R, Kind AC, Kirby WM, Johnson WL. Transplacental passage of methicillin and dicloxacillin into the fetus and amniotic fluid. Am J Obstet Gynecol. 1970;107(7):1054-1057. doi:10.1016/0002-9378(70)90628-9 [PubMed 5429971]
  19. Dicloxacillin [prescribing information]. Princeton, NJ: Sandoz Inc; November 2020.
  20. Dixon JM, Louis-Jacques A. Lactational mastitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed April 24, 2024.
  21. Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med, 1988, 318(7):419-26 and 318(8):490-500. [PubMed 3277054]
  22. Drivenes JL, Berg-Jensen M, Bygum A. A phototoxic drug reaction due to topical NSAIDs. Clin Case Rep. 2022;10(1):e05251. doi:10.1002/ccr3.5251 [PubMed 35079385]
  23. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis. 2003;36(suppl 1):S42-50. doi:10.1086/344653 [PubMed 12516029]
  24. Gosbell IB, Turnidge JD, Tapsall JW, Benn RA. Toxicities of flucloxacillin and dicloxacillin--is there really a difference?. Med J Aust. 2000;173(9):500-501. [PubMed 11149309]
  25. Isaksson B, Maller R, Nilsson LE, Nilsson M. Postantibiotic effect of aminoglycosides on staphylococci. J Antimicrob Chemother. 1993;32(2):215-222. doi:10.1093/jac/32.2.215 [PubMed 8226423]
  26. Ito S. Drug therapy for breast-feeding women. N Engl J Med. 2000;343(2):118-126. [PubMed 10891521]
  27. Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380(5):415-424. doi:10.1056/NEJMoa1808312 [PubMed 30152252]
  28. Johnson DW, Kay TD, Hawley CM. Severe hypokalaemia secondary to dicloxacillin. Intern Med J. 2002;32(7):357-358. doi:10.1046/j.1445-5994.2002.00243.x [PubMed 12088358]
  29. Jusko WJ, Mosovich LL, Gerbracht LM, et al. Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics. 1975; 56(6): 1038-1044. [PubMed 1196754]
  30. Kleinman MS, Presberg JE. Cholestatic hepatitis after dicloxacillin-sodium therapy. J Clin Gastroenterol. 1986;8(1):77-78. doi:10.1097/00004836-198602000-00017 [PubMed 3701014]
  31. Lamont HF, Blogg HJ, Lamont RF. Safety of antimicrobial treatment during pregnancy: a current review of resistance, immunomodulation and teratogenicity. Expert Opin Drug Saf. 2014;13(12):1569-1581. doi:10.1517/14740338.2014.939580 [PubMed 25189188]
  32. Li RC, Lee SW, Kong CH. Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action. J Antimicrob Chemother. 1997;40(1):39-45. doi:10.1093/jac/40.1.39 [PubMed 9249203]
  33. MacAulay MA, Berg SR, Charles D. Placental transfer of dicloxacillin at term. Am J Obstet Gynecol. 1968;102(8):1162-1168. doi:10.1016/0002-9378(68)90407-9 [PubMed 5699769]
  34. Matsuda S. Transfer of antibiotics into maternal milk. Biol Res Pregnancy Perinatol. 1984;5(2):57-60. [PubMed 6743732]
  35. Meyers RS, Thackray J, Matson KL, et al. Key Potentially Inappropriate Drugs in Pediatrics: The KIDs List. J Pediatr Pharmacol Ther. 2020;25(3):175-191. [PubMed 32265601]
  36. Mitchell KB, Johnson HM, Rodríguez JM, et al; Academy of Breastfeeding Medicine. Academy of Breastfeeding Medicine clinical protocol #36: the mastitis spectrum, revised 2022. Breastfeed Med. 2022;17(5):360-376. doi:10.1089/bfm.2022.29207.kbm [PubMed 35576513]
  37. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol. 2017a;83(11):2557-2571. doi:10.1111/bcp.13364 [PubMed 28722171]
  38. Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. CMAJ. 2017b;189(17):E625-E633. doi:10.1503/cmaj.161020 [PubMed 28461374]
  39. Muysson M, Datta P, Rewers-Felkins K, Baker T, Hale TW. Transfer of dicloxacillin into human milk. Breastfeed Med. Published online July 15, 2020. doi:10.1089/bfm.2020.0156 [PubMed 32678981]
  40. Nau H. Clinical pharmacokinetics in pregnancy and perinatology. II. Penicillins. Dev Pharmacol Ther. 1987;10(3):174-198. doi:10.1159/000457744 [PubMed 3301235]
  41. Nauta EH, Mattie H. Dicloxacillin and cloxacillin: pharmacokinetics in healthy and hemodialysis subjects. Clin Pharm and Ther. 1976;20(1): 98-108. [PubMed 1277730]
  42. Nielsen RM, Pallesen KA. Photoinduced acute exanthematous pustulosis caused by dicloxacillin and exposure to sunlight. Clin Case Rep. 2020;8(3):538-539. Published 2020 Feb 14. doi:10.1002/ccr3.2681 [PubMed 32185054]
  43. Osmon DR, Berbari EF, Berendt AR, et al, “Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,” Clin Infect Dis, 2013, 56(1):e1-25. [PubMed 23223583]
  44. Pacifici GM, Viani A, Taddeucci-Brunelli G, et al, “Plasma Protein Binding of Dicloxacillin: Effects of Age and Diseases,” Int J Clin Pharmacol Ther Toxicol, 1987, 25(11):622-6. [PubMed 3429065]
  45. Pries-Heje MM, Wiingaard C, Ihlemann N, et al. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. N Engl J Med. 2022;386(6):601-602. doi:10.1056/NEJMc2114046 [PubMed 35139280]
  46. Refer to manufacturer's labeling.
  47. Saavedra-Lozano J, Falup-Pecurariu O, Faust SN, et al. Bone and joint infections. Pediatr Infect Dis J. 2017;36(8):788-799. doi:10.1097/INF.0000000000001635 [PubMed 28708801]
  48. Seiga K, Yamaji K, Sugiyama Y. Distribution of ampicillin-dicloxacillin combination in the body. Article in Japanese, author's translation. Jpn J Antibiot. 1974;27(4):494-496. [PubMed 4436958]
  49. Smith AL, Meeks CA, Koup JR, Opheim KE, Weber A, Vishwanathan CT. Dicloxacillin absorption and elimination in children. Dev Pharmacol Ther. 1990;14(1):35-44. [PubMed 2311479]
  50. Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed June 17, 2022.
  51. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. doi:10.1093/cid/ciu444 [PubMed 24973422]
  52. Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs. Clin Infect Dis. 2023;76(3):487-496. doi:10.1093/cid/ciac714 [PubMed 36052413]
  53. Woods CR, Bradley JS, Chatterjee A, et al. Clinical Practice Guideline by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics. J Pediatric Infect Dis Soc. 2021;10(8):801-844. doi:10.1093/jpids/piab027 [PubMed 34350458]
  54. World Health Organization. (‎2000)‎. Mastitis: causes and management. World Health Organization. https://apps.who.int/iris/handle/10665/66230
  55. World Health Organization (WHO). Breastfeeding and maternal medication: recommendations for drugs in the eleventh WHO model list of essential drugs. Published 2002. https://apps.who.int/iris/handle/10665/62435
  56. Wright AJ, “The Penicillins,” Mayo Clin Proc, 1999, 74(3):290-307. [PubMed 10090000]
  57. Wu G, Zheng Y, Zhou H, et al. Safety and pharmacokinetics of dicloxacillin in healthy Chinese volunteers following single and multiple oral doses. Drug Des Devel Ther. 2015;9:5687-5695. doi:10.2147/DDDT.S92117 [PubMed 26527863]
Topic 9349 Version 290.0